NGNE CIK: 1404644

Neurogene Inc.

  • United States
  • Healthcare
  • Biotech
Metrics score locked — part of Premium
FY21
FY22
FY23
FY24
FY25
FY21 – FY25
(positive)
millions USD
FY21:
0
FY22:
–
FY23:
–
FY24:
–
FY25:
–
(positive)
Change from FY21 to FY25
millions USD
FY21:
−60.7
FY22:
−56.5
FY23:
−55.6
FY24:
−82.6
FY25:
−103
(positive)
Change from FY22 to FY25
millions USD
FY21:
–
FY22:
−52.0
FY23:
−49.4
FY24:
−72.5
FY25:
−87.3
(positive)
Change from FY21 to FY25
millions USD
FY21:
−60.7
FY22:
−55.2
FY23:
−36.3
FY24:
−75.1
FY25:
−90.4
(positive)
Change from FY21 to FY25
millions USD
FY21:
−60.7
FY22:
−55.2
FY23:
−36.3
FY24:
−75.1
FY25:
−90.4

All amounts in millions USD Data sources:SEC EDGARTwelve Data